Mylan Generic Infringes Sanofi's Uroxatral Patent: Judge
A federal judge has given Sanofi-Aventis SA a boost in its multidistrict litigation over competitors' attempts to market a generic version of prostate treatment Uroxatral, ruling at trial that the drug...To view the full article, register now.
Already a subscriber? Click here to view full article